**Supplementary Table 2. Grade of evidence about terlipressin compared to noradrenaline for hepatorenal syndrome**

|  |
| --- |
| **Terlipressin compared to noradrenaline for hepatorenal syndrome** |
| **Patient or population:** patients with hepatorenal syndrome**Settings:** hospital**Intervention:** terlipressin**Comparison:** noradrenaline |
| **Outcomes** | **Illustrative comparative risks\* (95% CI)** | **Relative effect(95% CI)** | **No of Participants(studies)** | **Quality of the evidence(GRADE)** | **Comments** |
| Assumed risk | Corresponding risk |
|  | **Noradrenaline** | **Terlipressin** |  |  |  |  |
| **HRS reversal** | **Study population** | **RR 1.17** (0.95 to 1.44) | 361(7 studies) | ⊕⊝⊝⊝**very low**1,2,3 | Downgraded because of risk of bias and inconsistency. |
| **434 per 1000** | **508 per 1000**(412 to 625) |
| **Moderate** |
| **500 per 1000** | **585 per 1000**(475 to 720) |
| **survival** | **Study population** | **RR 1.33** (1.01 to 1.76) | 252(4 studies) | ⊕⊝⊝⊝**very low**1,2,3 | Downgraded because of risk of bias and inconsistency. |
| **381 per 1000** | **507 per 1000**(385 to 670) |
| **Moderate** |
| **514 per 1000** | **684 per 1000**(519 to 905) |
| **serious adverse event** | **Study population** | **RR 1.2** (0.39 to 3.72) | 275(5 studies) | ⊕⊝⊝⊝**very low**1,2,3 | Downgraded because of risk of bias and inconsistency. |
| **36 per 1000** | **44 per 1000**(14 to 136) |
| **Moderate** |
| **0 per 1000** | **0 per 1000**(0 to 0) |
| \*The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).**CI:** Confidence interval; **RR:** Risk ratio;  |
| GRADE Working Group grades of evidence**High quality:** Further research is very unlikely to change our confidence in the estimate of effect. **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.**Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.**Very low quality:** We are very uncertain about the estimate. |
| 1 risk of bias2 outcomes different3 small patients |